Health Commissioner Stella said: “The EMA is very clear: the benefits of the Johnson & Johnson vaccine against covid-19 outweigh the risks of very rare and unusual side effects. I urge all EU member states to follow our expert opinions.” Kyriakides.
Brussels (Euro News Agency). -Health Commissioner Stella Kyriakides (Stella Kyriakides) emphasized that the European Medicines Agency’s (EMA) conclusion on the safety of Janssen’s covid-19 vaccine is “clear” and shows that its benefits are greater than Risk, so he asked European governments to follow the advice of health agencies.
The executive head of the community, Ursula von der Leyen, also talked about this on the same social network. He praised EMA’s analysis and assured that this is “good news” for the vaccination campaign in the region.
Kyriakides and Von der Leyen reacted this way shortly after hearing the conclusions of the EMA Safety Committee (PRAC) on the profit risk analysis of the formula developed by Janssen (a subsidiary of Johnson & Johnson).
Specifically, PRAC concluded that despite the discovery of “very rare cases” of abnormal blood clots associated with low platelets, which may be a trigger for thrombosis, the benefits of vaccination outweigh the risks of not injecting.
Therefore, the EMA determined that a warning should be added to the product information of the Janssen vaccine, and these events should be included as very rare side effects of the vaccine.
The EU expects to receive a total of 55 million doses of this vaccine between April and June, of which about 5.5 million units will be used in Spain. The first dose of the drug was distributed to Member States last Monday, but no drug has been administered until the EMA’s opinion has not been decided.